How I treat and manage strokes in sickle cell disease.

Kassim AA, Galadanci NA, Pruthi S, DeBaun MR
Blood. 2015 125 (22): 3401-10

PMID: 25824688 · PMCID: PMC4467906 · DOI:10.1182/blood-2014-09-551564

Neurologic complications are a major cause of morbidity and mortality in sickle cell disease (SCD). In children with sickle cell anemia, routine use of transcranial Doppler screening, coupled with regular blood transfusion therapy, has decreased the prevalence of overt stroke from ∼11% to 1%. Limited evidence is available to guide acute and chronic management of individuals with SCD and strokes. Current management strategies are based primarily on single arm clinical trials and observational studies, coupled with principles of neurology and hematology. Initial management of a focal neurologic deficit includes evaluation by a multidisciplinary team (a hematologist, neurologist, neuroradiologist, and transfusion medicine specialist); prompt neuro-imaging and an initial blood transfusion (simple followed immediately by an exchange transfusion or only exchange transfusion) is recommended if the hemoglobin is >4 gm/dL and <10 gm/dL. Standard therapy for secondary prevention of strokes and silent cerebral infarcts includes regular blood transfusion therapy and in selected cases, hematopoietic stem cell transplantation. A critical component of the medical care following an infarct is cognitive and physical rehabilitation. We will discuss our strategy of acute and long-term management of strokes in SCD.

© 2015 by The American Society of Hematology.

MeSH Terms (10)

Adolescent Adult Anemia, Sickle Cell Diagnosis, Differential Female Humans Magnetic Resonance Imaging Male Neuroimaging Stroke

Connections (1)

This publication is referenced by other Labnodes entities: